Brief: PDS Biotech Plans To Initiate Phase 3 Study Evaluating PDS0101 With KEYTRUDA

PDS Biotechnology

30/03/2023 13:56

March 30 (Reuters) - PDS Biotechnology Corp  PDSB.O :
    * PDS BIOTECH ANNOUNCES PLAN TO INITIATE PHASE 3 STUDY
EVALUATING
PDS0101 IN COMBINATION WITH KEYTRUDA® IN HEAD AND NECK CANCER IN
2023
    * PDS BIOTECH ANNOUNCES PLAN TO INITIATE PHASE 3 STUDY
EVALUATING
PDS0101 IN COMBINATION WITH KEYTRUDA® IN HEAD AND NECK CANCER IN
2023
    * PDS BIOTECHNOLOGY CORP - PLANS TO SUBMIT AN AMENDED
INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO FDA IN Q3 OF 2023
    * PDS BIOTECHNOLOGY CORP - VERSATILE-003 IS EXPECTED TO
INVOLVE
ABOUT 90-100 CLINICAL SITES GLOBALLY
    * PDS BIOTECHNOLOGY CORP - VERSATILE-003 IS EXPECTED TO
INVOLVE
APPROXIMATELY 90-100 CLINICAL SITES GLOBALLY

Source text for Eikon:  ID:nGNX5sdfV6 
Further company coverage:  PDSB.O 

 ((Reuters.Briefs@thomsonreuters.com;))